Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.

Breast cancer research and treatment - 1 Nov 2018

Bae Soo Youn, Nam Seok Jin, Jung Yongsik, Lee Sae Byul, Park Byung-Woo, Lim Woosung, Jung Sung Hoo, Yang Hsien Wen, Jung Seung Pil

Abstract excerpt

PURPOSE: TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. METHODS: A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Disease-Free Survival

Share to Mutation

Share to Prognosis

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 30132220
DOI: 10.1007/s10549-018-4928-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.PMID 30132220Read ↗

TP53 signature score predicts prognosis and immune response in triple-negative breast cancerSemantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.Semantic proximity Read ↗

Molecular subtypes and precision treatment of triple-negative breast cancerSemantic proximity Read ↗

Is triple negative a prognostic factor in breast cancer?Semantic proximity Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read ↗

Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.Semantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

Risk factors, prognostic factors, and nomograms for distant metastasis in patients with triple-negative breast cancer: a population-based studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.